Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 4/20 | 0.48 |
| ▸ | TEK | Q02763 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 3/20 | 0.41 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888910 | 0.80 | TEK (0.51) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL15729226 | 0.79 | LOXL2 (0.52) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL16597377 | 0.79 | TEK (0.54) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL19932617 | 0.79 | TEK (0.50) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL12516034 | 0.79 | EPHB4 (0.50) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL12049658 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL17091179 | 0.77 | LOXL2 (0.51) | EPHB4TEKKDRKCNH2CHRM1 | |
| SCHEMBL198803 | 0.77 | ERN1 (0.47) | — | |
| SCHEMBL5990507 | 0.77 | CLK1 (0.51) | KDRMKNK1MKNK2CCNCCDK8 | |
| SCHEMBL25242176 | 0.76 | MAPK8 (0.51) | EPHB4TEKKDRCHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512426-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-20150132761-A1 | METHOD FOR RAPIDLY EVALUATING PERFORMANCE OF SHORT INTERFERING RNA WITH NOVEL CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-05-14 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877439-B2 | Method for rapidly evaluating performance of short interfering RNA with novel chemical modifications | SIRNA THERAPEUTICS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | EPHB4 4336/4885TEK 2329/4885KDR 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.